psalexa
logo

Acne Vulgaris Therapeutics

Acne Vulgaris Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, Epidemiology Forecast to 2023, and Unmet Needs within the Market

Published: November 2017
Report Code: LS11275
Available Format:
Pages: 157

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Acne Vulgaris Disease Overview

4.1.1 Signs and Symptoms

4.1.2 Pathophysiology

4.1.3 Diagnosis

4.1.4 Etiology

4.1.5 Treatment

4.1.6 Prognosis

4.2 Key Drivers

4.2.1 Increased early stage drug candidates

4.2.2 Positive Clinical Results

4.2.3 XXXX

4.3 Key Barriers

4.3.1 Topical Route of Administration Causes Low Bioavailability

4.4 Acne Vulgaris Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Acne Vulgaris Epidemiology and Patient Population Forecast to 2023 for 7MM

5.1 U.S.

5.2 U.K.

5.3 France

5.4 Germany

5.5 Italy

5.6 Spain

5.7 Japan

Chapter 6. Acne Vulgaris Therapeutics Pipeline Analysis by Phase (2017)

6.1 Filed

6.1.1 DFD-10

6.1.1.1 Strategic development

6.2 Phase III

6.2.1 KW303

6.2.2 XXXX

6.2.2.1 Clinical trials

6.2.3 XXXX

6.2.4 XXXX

6.2.4.1 Pre-Clinical study

6.2.4.2 Clinical trials

6.2.5 XXXX

6.2.5.1 Clinical trials

6.2.5.2 Strategic development

6.2.6 XXXX

6.2.6.1 Clinical trials

6.2.7 XXXX

6.2.7.1 Clinical trials

6.2.7.2 Clinical results

6.2.8 XXXX

6.2.8.1 Clinical trials

6.2.9 XXXX

6.2.10 XXXX

6.2.10.1 Clinical trials

6.2.11 XXXX

6.2.11.1 Clinical trials

6.2.11.2 Strategic development

6.2.12 XXXX

6.2.12.1 Clinical trials

6.2.12.2 Strategic development

6.2.13 XXXX

6.2.13.1 Clinical trials

6.3 Phase II/III

6.3.1 B 244

6.3.1.1 Clinical trials

6.4 Phase II

6.4.1 Visonac

6.4.1.1 Clinical trials

6.4.2 XXXX

6.4.2.1 Clinical trials

6.4.2.2 Strategic development

6.4.3 XXXX

6.4.3.1 Clinical trials

6.4.4 XXXX

6.4.4.1 Clinical trials

6.4.5 XXXX

6.4.5.1 Clinical trials

6.4.5.2 Strategic development

6.4.6 XXXX

6.4.6.1 Clinical trials

6.4.6.2 Strategic development

6.4.7 XXXX

6.4.7.1 Clinical trials

6.4.8 XXXX

6.4.8.1 Clinical trials

6.4.9 XXXX

6.4.9.1 Clinical trials

6.4.10 XXXX

6.4.10.1 Clinical trials

6.4.11 XXXX

6.4.11.1 Clinical trials

6.4.11.2 Strategic development

6.4.12 XXXX

6.4.12.1 Clinical trials

6.4.13 XXXX

6.4.13.1 Clinical trials

6.4.13.2 Strategic development

6.4.14 XXXX

6.4.14.1 Clinical trials

6.4.15 XXXX

6.4.15.1 Clinical trials

6.4.16 XXXX

6.4.16.1 Clinical trials

6.5 Phase I

6.5.1 XXXX

6.5.1.1 Clinical trials

6.5.2 XXXX

6.5.3 XXXX

6.5.3.1 Clinical trials

6.6 Pre-Clinical

6.6.1 XXXX

6.6.1.1 Pre-Clinical results

6.6.2 XXXX

6.6.3 XXXX

6.6.4 XXXX

6.6.5 XXXX

6.7 Discovery

6.7.1 Acne Vulgaris Vaccine - Origimm

6.7.2 XXXX

6.8 Unknown

6.8.1 Peptide - Helix Biomedix, Inc.

6.8.2 XXXX

6.8.3 XXXX

6.8.4 XXXX

6.8.5 XXXX

6.8.6 XXXX

6.8.7 XXXX

6.8.8 XXXX

Chapter 7. Clinical Trials Analysis

7.1 Clinical Trials, by Region

7.2 Clinical Trials, by Trial Status

Chapter 8. Competitive Landscape

8.1 Key Players Benchmarking for Acne Vulgaris Therapeutics Pipeline

8.2 SWOT Analysis of Acne Vulgaris Therapeutics Pipeline

8.2.1 Strengths

8.2.2 Weaknesses

8.2.3 Opportunities

8.2.4 Threats

Chapter 9. Company Profiles

9.1 AndroScience Corporation

9.1.1 Business Overview

9.1.2 Product and Service Offerings

9.2 XXXX

9.2.1 Business Overview

9.2.2 Product and Service Offerings

9.3 XXXX

9.3.1 Business Overview

9.3.2 Product and Service Offerings

9.4 XXXX

9.4.1 Business Overview

9.4.2 Product and Service Offerings

9.5 XXXX

9.5.1 Business Overview

9.5.2 Product and Service Offerings

Chapter 10. Appendix

10.1 Abbreviations

10.2 Related Reports

 

LIST OF TABLES

   

TABLE 1:

PIPELINE ANALYSIS OF ACNE VULGARIS BY COMPANY (2017)

TABLE 2:

ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN 7MM, ‘000 (2016–2023)

TABLE 3:

ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN THE U.S., ‘000 (2016–2023)

TABLE 4:

ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN U.K., ‘000 (2016–2023)

TABLE 5:

ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN FRANCE, ‘000 (2016–2023)

TABLE 6:

ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN GERMANY, ‘000 (2016–2023)

TABLE 7:

ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN ITALY, ‘000 (2016–2023)

TABLE 8:

ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN SPAIN, ‘000 (2016–2023)

TABLE 9:

ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN JAPAN, ‘000 (2016–2023)

TABLE 10:

DESCRIPTION OF DFD-10

TABLE 11:

DESCRIPTION OF KW303

TABLE 12:

DESCRIPTION OF XXX

TABLE 13:

CLINICAL TRIALS OF XXXX

TABLE 14:

DESCRIPTION OF XXXX

TABLE 15:

DESCRIPTION OF XXXX

TABLE 16:

CLINICAL TRIALS OF XXXX

TABLE 17:

DESCRIPTION OF XXXX

TABLE 18:

CLINICAL TRIALS OF XXXX

TABLE 19:

DESCRIPTION OF IDP XXXX

TABLE 20:

CLINICAL TRIALS OF XXXX

TABLE 21:

DESCRIPTION OF XXXX

TABLE 22:

CLINICAL TRIALS OF XXXX

TABLE 23:

DESCRIPTION OF XXXX

TABLE 24:

CLINICAL TRIALS OF XXXX

TABLE 25:

DESCRIPTION OF XXXX

TABLE 26:

DESCRIPTION OF XXXX

TABLE 27:

CLINICAL TRIALS OF XXXX

TABLE 28:

DESCRIPTION OF XXXX

TABLE 29:

CLINICAL TRIALS OF XXXX

TABLE 30:

DESCRIPTION OF XXXX

TABLE 31:

CLINICAL TRIALS OF XXXX

TABLE 32:

DESCRIPTION OF XXXX

TABLE 33:

CLINICAL TRIALS OF XXXX

TABLE 34:

DESCRIPTION OF B 244

TABLE 35:

CLINICAL TRIALS OF B 244

TABLE 36:

DESCRIPTION OF VISONAC

TABLE 37:

CLINICAL TRIALS OF VISONAC

TABLE 38:

DESCRIPTION OF XXXX

TABLE 39:

CLINICAL TRIALS OF XXXX

TABLE 40:

DESCRIPTION OF XXXX

TABLE 41:

CLINICAL TRIALS OF XXXX

TABLE 42:

DESCRIPTION OF XXXX

TABLE 43:

CLINICAL TRIALS OF XXXX

TABLE 44:

DESCRIPTION OF XXXX

TABLE 45:

CLINICAL TRIALS OF XXXX

TABLE 46:

DESCRIPTION OF XXXX

TABLE 47:

CLINICAL TRIALS OF XXXX

TABLE 48:

DESCRIPTION OFXXXX

TABLE 49:

DESCRIPTION OF XXXX

TABLE 50:

CLINICAL TRIALS OF XXXX

TABLE 51:

DESCRIPTION OF XXXX

TABLE 52:

DESCRIPTION OF XXXX

TABLE 53:

CLINICAL TRIALS OF XXXX

TABLE 54:

DESCRIPTION OF XXXX

TABLE 55:

CLINICAL TRIALS OF XXXX

TABLE 56:

DESCRIPTION OF XXXX

TABLE 57:

CLINICAL TRIALS OF XXXX

TABLE 58:

DESCRIPTION OF XXXX

TABLE 59:

CLINICAL TRIALS OF XXXX

TABLE 60:

DESCRIPTION OF XXXX

TABLE 61:

CLINICAL TRIALS OF XXXX

TABLE 62:

DESCRIPTION OF XXXX

TABLE 63:

CLINICAL TRIALS OF XXXX

TABLE 64:

DESCRIPTION OF XXXX

TABLE 65:

CLINICAL TRIALS OF XXXX

TABLE 66:

DESCRIPTION OF XXXX

TABLE 67:

CLINICAL TRIALS OF XXXX

TABLE 68:

DESCRIPTION OF XXXX

TABLE 69:

DESCRIPTION OF XXXX

TABLE 70:

DESCRIPTION OF XXXX

TABLE 71:

DESCRIPTION OF XXXX

TABLE 72:

DESCRIPTION OF XXXX

TABLE 73:

DESCRIPTION OF XXXX

TABLE 74:

DESCRIPTION OF XXXX

TABLE 75:

DESCRIPTION OF ACNE VULGARIS VACCINE - ORIGIMM

TABLE 76:

DESCRIPTION OF XXXX

TABLE 77:

DESCRIPTION OF PEPTIDE – HELIX BIOMEDIX, INC.

TABLE 78:

DESCRIPTION OF XXXX

TABLE 79:

DESCRIPTION OF XXXX

TABLE 80:

DESCRIPTION OF XXXX

TABLE 81:

DESCRIPTION OF XXXX

TABLE 82:

DESCRIPTION OF XXXX

TABLE 83:

DESCRIPTION OF XXXX

TABLE 84:

DESCRIPTION OF XXXX

TABLE 85:

ANDROSCIENCE CORPORATION – AT A GLANCE

TABLE 86:

XXXX – AT A GLANCE

TABLE 87:

XXXX - KEY FACTS

TABLE 88:

XXXX– AT A GLANCE

TABLE 89:

XXXX – AT A GLANCE

 

LIST OF FIGURES

 

FIG 1: RESEARCH METHODOLOGY

FIG 2: SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3: BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 4: BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 5: TOTAL PREVALENT CASES OF ACNE VULGARIS (2016-2023)

FIG 6: NUMBER OF ACNE VULGARIS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

FIG 7: ACNE VULGARIS PIPELINE SPLIT, BY MOLECULE TYPE (2017)

FIG 8: ACNE VULGARIS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

FIG 9: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN 7MM (2016–2023)

FIG 10: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN THE U.S. (2016–2023)

FIG 11: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN U.K. (2016–2023)

FIG 12: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN FRANCE (2016–2023)

FIG 13: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN GERMANY, (2016–2023)

FIG 14: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN ITALY (2016–2023)

FIG 15: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN SPAIN (2016–2023)

FIG 16: ACNE VULGARIS THERAPEUTICS, TREATMENT USAGE PATTERN IN JAPAN (2016–2023)

FIG 17: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 18: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 19: KEY PLAYERS BENCHMARKING

FIG 20: SWOT ANALYSIS

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry